The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in prostate cancer:

PROTOCOL: (MK3475-641) (PI: DR PRETORIA BILINSKI)
SHORT TITLE: KEYNOTE 641

Protocol Title: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Lay Title: Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Click here for more information

PROTOCOL: C3441052 (TALAPRO-3) (PI: DR JEFF GOH)

Protocol Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Lay Title: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Click here for more information

RETURN TO CLINICAL TRIALS PAGE